Use of Zeaxanthin For the Treatment of Diseases of the Peripheral Retina

The use of zeaxanthin in the manufacture of a composition for oral application to the human body for the treatment or prevention of diseases of the peripheral retina selected from the group consisting of all forms of inherited or non-inherited Retinitis Pigmentosa in general, and Night Blindness (inherited, or vitamin A dependent), fundus albipunctatus, retinitis punctata albescens, Bothnia disease, Leber congenital amaurosis. Stargardt disease, Fundus flavimaculatus, Rod-cone dystrophy, Refsum disease, Bardet-Biedi (Laurence-Moon) syndrome, Best disease, Choroideremia, Gyrate-atrophy Usher syndrome, Batton disease (also known as juvenile neuronal ceroid lipofuscinosis) Bietti crystalline comeoretinal dystrophy;

• Wagner vitreoretinal degeneration, Stickler syndrome and abetalipo-.proteinaemia, wherein the daily dosage of zeaxanthin is within the range of from 0.001 mg per kg body weight to about 20 mg per kg body weight, preferably from about 0.01 to about 10 mg per kg body weight, and most preferably from about 0.1 to 1.0 mg per kg body weight per day.